Molina Ana M, Nanus David M
Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, 1300 York Avenue, New York, NY, 10065 , USA; Meyer Cancer Center, Weill Cornell Medicine, 1300 York Avenue, New York, NY, 10065 , USA.
F1000Res. 2016 Mar 23;5. doi: 10.12688/f1000research.7935.1. eCollection 2016.
Therapeutic options for patients with metastatic renal cell carcinoma have significantly improved over the past few years with the recent approval of two new agents resulting in prolonged progression-free and overall survival.
在过去几年中，随着两种新药物最近获批，转移性肾细胞癌患者的治疗选择有了显著改善，从而延长了无进展生存期和总生存期。
